Tag Archives: events

Lack Of Earnings Quality And Debt Downgrades Limit S&P 500’s Upside

Four in a row. That’s how many consecutive 3-point baskets Andre Iguodala scored against the Houston Rockets in last night’s playoff game. There has also been a “4 for 4″ in the financial markets. One after another, major banks have lowered their year-end targets for the S&P 500. Most recently, the global equity team at HSBC shaved its year-end target to 2,050 from 2,100. On the surface, HSBC’s cut is less severe than other bank revisions to S&P 500 estimates. That said, J.P Morgan pulled its projection all the way down from 2200 to 2000. Credit Suisse? Down to 2,050 from 2,200. And Morgan Stanley slashed its year-end projection from 2175 to 2050. So what’s going on? We had four influential banks expressing confidence in the popular benchmark a few months earlier. Their analysts originally projected total returns with reinvested dividends between 5%-10% in the present 12-month period. Now, however, with the S&P 500 only expected to finish between 2000-2050, these banks see the index offering a paltry 0%-2%. Another way some have phrased it? Excluding dividends, there is “zero upside.” Here is yet another “4 for 4” that makes a number of analysts uncomfortable. Year-over-year quarterly earnings have fallen four consecutive times. That has not happened since the Great Recession. And revenue? Corporations have put forward year-over-year declines in sales growth for five consecutive quarters. That hasn’t happened since the Great Recession either. The bullish investor case is that the trend is going to start reversing itself in the 2nd half of 2016. However, forward estimates of earnings growth and revenue growth are routinely lowered so that two-thirds or more companies can surpass “expectations.” And it is not unusual for estimates to be lowered by 10%. Take Q1. Shortly before the start of the year, Q1 estimates had been forecast to come in at a mild gain. Today? We’re looking at -9% or worse for Q1. Over the previous five years, Forward P/Es averaged 14.5. They now average 16.5 on earning estimates that will never be realized. In essence, S&P 500 stock prices are sitting a softball’s throw away from an all-time record (2130), while the forward P/E valuations sit at bull market extremes that do not justify additional appreciation in price. And what about earnings quality? Wall Street typically presents two kinds: Generally Accepted Accounting Principles (GAAP) earnings and non-GAAP earnings that excludes special items, non-recurring expenses and a wide variety on “one-time charges.” The foolishness of non-GAAP presentations notwithstanding, one might disregard the manipulation when non-GAAP and GAAP are within the usual 10% range. This was more or less the case between 2009 and 2013. By 2014, however, the gap between the two different earnings per share reports began to widen. By 2015, “manipulated” pro forma ex-items earnings exceeded actual earnings per share by roughly $250 billion, or 32%. Can you spell c-h-i-c-a-n-e-r-y? Of particular interest, there was a similar disconnect between GAAP and non-GAAP in 2007. Non-GAAP in the year when the last bear market began (10/07) was 24% higher than GAAP earnings per share. It follows that the discrepancy today in earnings quality is even wider than it was prior to the stock market collapse. “But Gary,” you protest. “As long as the Federal Reserve and central banks are exceptionally accommodating, stocks should excel.” In truth, however, the long-term relationship between the SPDR S&P 500 Trust ETF (NYSEARCA: SPY ) and the Vanguard Total Bond Market ETF (NYSEARCA: BND ) demonstrate that the bond component of one’s portfolio has been more productive over the last 12 months than the stock component. Bulls can point to the market’s eventual ability to shake off the euro-zone crisis of 2011. That was the last time that the SPY:BND price ratio struggled for an extended length of time. Back then, however, the Federal Reserve offered two aggressive easing policies – “Operation Twist” and “QE 3.” Today? Stocks are not only extremely overvalued on most historical measures, but the Fed has only lowered its tightening guidance from four hikes down to two hikes. Is that really enough ammunition to power stocks to remarkable new heights? “Okay,” you acknowledge. “But rates are so low, they are even lower than they were in 2013. And that means, going forward, there is no alternative to stocks.” Not only does history dispel the myth that there are no alternatives to stocks , but many corporations that have been buying back their stocks at attractive borrowing costs are now at risk of debt downgrades, higher interest expenses and even default. For example, the moving 12-month sum of Moody’s debt downgrades hopped from 32 a year ago to 61 in March of 2016. Meanwhile, the longer-term trend for the widening of credit spreads between investment grade treasuries in the iShares 7-10 Year Treasury Bond ETF (NYSEARCA: IEF ) and high yield bonds in the iShares iBoxx $ High Yield Corporate Bond ETF (NYSEARCA: HYG ) suggest that the corporate debt binge may soon come to an ignominious end. Foreign stocks, emerging market stocks as well as high yield bonds all hit their cyclical tops in mid-2014, when the credit spreads were remarkably narrow. The IEF:HYG price ratio spikes and breakdowns notwithstanding, the general trend for 18-plus months has been less favorable to lower-rated corporate borrowers. The implication? With corporate credit conditions worsening at the fastest pace since the financial crisis , companies may be forced to slow or abandon stock share buybacks. What group of buyers will pick up the slack when valuation extremes meet fewer stock buybacks? Click here for Gary’s latest podcast. Disclosure: Gary Gordon, MS, CFP is the president of Pacific Park Financial, Inc., a Registered Investment Adviser with the SEC. Gary Gordon, Pacific Park Financial, Inc, and/or its clients may hold positions in the ETFs, mutual funds, and/or any investment asset mentioned above. The commentary does not constitute individualized investment advice. The opinions offered herein are not personalized recommendations to buy, sell or hold securities. At times, issuers of exchange-traded products compensate Pacific Park Financial, Inc. or its subsidiaries for advertising at the ETF Expert web site. ETF Expert content is created independently of any advertising relationships.

The Remarkable Investing Power Of ‘Creative Destruction’

Originally published on March 29, 2016 International Business Machines Corporation (NYSE: IBM ) is soon set to celebrate its 105-year anniversary – an astonishing achievement for any single company, let alone one in the dynamic and changing technology sector. “Big Blue” is a remarkable exception in a world where companies come and go – and yesterday’s “heroes” become today’s “zeroes.” Yet, this very “creative destruction” that makes companies come and go is a crucial factor in the long-term success of any investment strategy. That’s also why – for your long-term investment success – picking the right country, market or sector is much more important than picking any single company or stock. The Accelerating Pace of “Creative Destruction” Austrian economist Joseph Schumpeter popularized the phrase “creative destruction” in the 1940s. It is the idea that the engine of capitalism is the continuous creation of new ideas and new products, where the new pushes out the old. You see examples of creative destruction throughout the history of the U.S. stock market. In the 1920s, the Radio Corporation of America (RCA) was the “Google” (NASDAQ: GOOG ) (NASDAQ: GOOGL ) of its day – a fast-growing company with new technology that changed the way an entire generation of Americans communicated. RCA actually lived a remarkably long life, born in 1919 and passing on in 1986. And in today’s world of exponential change, the pace of this “creative destruction” is accelerating even as the average life span of companies is shrinking. A mere decade ago, everywhere you looked, people either had Motorola phones (in the United States) or Nokia (everywhere else in the world). Or they carried BlackBerries, manufactured by Canada’s Research in Motion (RIMM) (NASDAQ: BBRY ) . Today, Motorola’s cell phone business Motorola Mobility Holdings, Inc. is part of Chinese-owned Lenovo ( OTCPK:LNVGY ), even as its market share has all but disappeared. Nokia (NYSE: NOK ) was eventually acquired by Microsoft (NASDAQ: MSFT ). And the market share of Research in Motion has fallen off a cliff. Indeed, the company’s market share in the businesses it dominated just a few years ago continues to evaporate. The fate of Research in Motion and Nokia echoes that of Palm – a once-high-flying company that hit a share price of $95.06 in 2000 – only to be acquired by HP (NYSE: HPQ ) for $5.70 a decade later. Once a company hits a death spiral, few make it out of the dive toward oblivion. Palm, a once-pioneering company in the world of “personal digital assistants,” was eventually sold to the Chinese electronics firm TCL Corporation. And it hasn’t been heard from since. Even companies that don’t disappear end up mere shadows of their former selves. Cisco (NASDAQ: CSCO ) , once expected to be the first $1 trillion company, today is worth less than 15% of that lofty amount. Former tech giant Lucent Technologies retired to the 7th Arrondissement Paris in 2006, acquired by France’s Alcatel. The surprising thing is that – from a long-term perspective – the same fate likely awaits today’s tech-darlings Alphabet and Apple (NASDAQ: AAPL ) , as well. The Myth of “One Decision” Stock Investing The fate of these former rising-star companies highlights the challenges of “one decision” investing, espoused by Warren Buffett. When Buffett buys a stock, his ideal holding period is “forever.” And this worked for him remarkably well… Until it didn’t… Over the last 51 years – since he acquired it – Berkshire Hathaway’s (NYSE: BRK.A ) (NYSE: BRK.B ) book value has grown from $19 to $157,000 – a rate of 19.36% compounded annually. That number, however, conceals more than it reveals. First, Buffett’s average rate of return up until about 2000 was right around 30%. But Buffett’s long-term investment returns have plummeted over 30% during just the past 15 years. The numbers bear this out. On June 19, 1998, Berkshire’s share price was $80,900. On Friday, March 24 2016, it closed at $210,530. That works out to a very un-Buffett-like annual return of only 5.45% a year for the last 18 years. And that’s more than just a streak of bad luck. After all, 18 years is close to 35% of Berkshire’s entire lifetime under Buffett’s stewardship. Viewed through the lens of “creative destruction,” you could argue that the lack of growth from new companies and new ideas with potential exponential growth are behind Berkshire’s flagging returns. The Unexpected Lesson Over the long term, the more a country or a sector provides for an environment of “creative destruction,” the better. And in practice, that means betting on both tech and small-cap stocks, as both have the potential to generate exponential returns old stalwarts simply cannot. According to Yale endowment Chief David Swensen, had you invested your money in a U.S. small-cap index in 1932, you’d have made 15,600 times your money between then and 2008. And I bet there were very few individual companies in that index in 1932 that made it to 2008. After all, 1932 was a long time ago… Warren Buffett was two years old. Hitler had not yet come to power in Germany. The United States and the Western world were in the midst of a Great Depression. Television, jet planes and computers had yet to be invented. At the same time, nowhere else but in the United States, where “creative destruction” is part of the very fiber of economic life, could you have generated those kind of returns. So, the next time you invest, ask yourself whether the companies in that sector will be the same ones tomorrow as they are today… And if the names aren’t changing, take heed… That’s because the greater the “creative destruction” in a sector, the greater chance for potential profits… Just make sure you bet on the winners.

Healthcare Mutual Funds To Bounce Back After Q1 Debacle: 5 Picks

The healthcare space was mostly out of favor in the first quarter following Democratic Presidential Candidate, Hillary Clinton’s allegation on “price gouging.” The massive decline in Valeant Pharmaceuticals International, Inc.’s (NYSE: VRX ) shares also had an adverse impact on biotech stocks, eventually dragging the healthcare sector down. Healthcare mutual funds weren’t spared as the category turned out to be the worst performer in the first quarter. Foremost funds from the healthcare space failed to end in positive territory during the period. Despite this hiccup, investors shouldn’t be demoralized as the long term bodes well for such funds. The healthcare sector is poised to gain from an ageing population both at home and abroad. And with an increase in mergers, and innovative product pipelines and approvals, it’s just a matter of time before the sector bounces back. Not to forget that biotech stocks have already rebounded in the past few days after being torn apart in the first three months of the year. Banking on this optimism, it will be prudent to invest in healthcare funds that have given solid returns over a long period of time and also boast strong fundamentals. (Read: 3 Healthcare Funds to Buy on Biotech Rebound ) Healthcare Losing Ground in Q1 It’s been an awful first quarter for the healthcare sector. Political scrutiny about drug prices took a toll on healthcare stocks. Healthcare Equity Funds nosedived 13.28% during the first quarter, according to Morningstar. Among the worst performing drug makers were Mallinckrodt Public Limited Company (NYSE: MNK ), Horizon Pharma plc (NASDAQ: HZNP ) and Endo International plc (NASDAQ: ENDP ), whose shares plunged 17.9%, 21.4% and 54%, respectively, in the first quarter. If you think that was bad, then biotechs had it even worse. The iShares NASDAQ Biotechnology Index plummeted almost 23% in the first quarter. The Valeant Pharmaceuticals disaster was also responsible for the significant underperformance. U.S. lawmakers investigating Valeant’s pricing practices, accusations about accounting irregularities and delay in filing annual reports practically ruined the company. In the first quarter alone, Valeant’s shares plummeted 36.8%. With the new tax inversion rules the pain seems to have intensified. According to the U.S. Treasury Department and Internal Revenue Service, the rule bars U.S. companies from undertaking inversion transactions if they have done so in the past three years. These inversion deals were a ploy for U.S. drug companies to dodge tax bills by relocating their headquarters abroad. On the earnings front, things are also looking gloomy. First-quarter earnings from the healthcare sector are anticipated to grow a meager 0.6% from the year-ago level compared with 9.3% growth witnessed in the previous quarter. (Read: Previewing the Q1 Earnings Season ) Tailwinds are Strong Even though healthcare witnessed a dismal first quarter, the sector is positioned to grow in the future thanks to an ageing American population. There are about 77 million U.S. baby boomers, which is quite a significant number. An ageing population bodes well for the healthcare sector as they require more medical attention. Along with it, an ageing China also provides long-term opportunities for both U.S. pharmaceutical and medical technology companies. The need to trim costs and tap growth opportunities are driving healthcare firms into mergers and acquisitions (M&A). Additionally, the Fed’s dovish outlook to proceed cautiously on hiking rates is also expected to boost M&A deals. Also, the first FDA-approved biosimilar, Zarxio, hit the market last year. Biotech companies are now vying to enter this high revenue generating space. Several other products such as Imlygic, Ibrance, Strensiq, Genvoya and, PCSK9 inhibitors, Praluent and Repatha also got approved. This in turn is expected to help companies from the healthcare space to generate steady revenues. Thanks to the mandated healthcare coverage in the U.S., more Americans are seeking treatment, which is also a net positive for healthcare firms. 5 Healthcare Mutual Funds to Invest In As discussed above, these tailwinds may collectively act as growth facilitators and help the healthcare sector overcome the drubbing it took in the first quarter. In case of inversion rules, healthcare companies will continue to seek creative ways to relocate their tax residence to avoid paying the lofty taxes at home, as per the Treasury Secretary Jacob J. Lew. Since the long run holds good for the healthcare sector, it will be wise to buy mutual funds associated with the sector. These funds have yielded positive returns for a long time despite being in the red in the first quarter. Moreover, these funds are fundamentally solid, which will eventually help them gain in the future as well. We have selected five healthcare mutual funds that have impressive 3-year and 5-year annualized returns and carry a Zacks Mutual Fund Rank #1 (Strong Buy) or #2 (Buy). These funds also possess a relatively low expense ratio and have minimum initial investment within $5000. T. Rowe Price Health Sciences Fund (MUTF: PRHSX ) invests a large portion of its assets in companies engaged in the development and distribution of health care products. PRHSX’s 3-year and 5-year annualized returns are 19.7% and 21.1%, respectively. Annual expense ratio of 0.76% is lower than the category average of 1.35%. PRHSX has a Zacks Mutual Fund Rank #1. Fidelity Select Health Care Portfolio (MUTF: FSPHX ) invests a major portion of its assets in companies involved in the manufacture and sale of products used in connection with health care. FSPHX’s 3-year and 5-year annualized returns are 19.2% and 18.8%, respectively. Annual expense ratio of 0.74% is lower than the category average of 1.35%. FSPHX has a Zacks Mutual Fund Rank #2. Hartford Healthcare Fund A (MUTF: HGHAX ) invests the majority of its assets in the equity securities of health care-related companies worldwide. HGHAX’s 3-year and 5-year annualized returns are 17.3% and 17.7%, respectively. Annual expense ratio of 1.28% is lower than the category average of 1.35%. HGHAX has a Zacks Mutual Fund Rank #2. Live Oak Health Sciences Fund (MUTF: LOGSX ) invests a large portion of its assets in equity securities of health sciences companies. LOGSX’s 3-year and 5-year annualized returns are 16.1% and 15.7%, respectively. Annual expense ratio of 1.08% is lower than the category average of 1.35%. LOGSX has a Zacks Mutual Fund Rank #2. Fidelity Select Biotechnology Portfolio (MUTF: FBIOX ) invests the majority of its assets in companies engaged in the manufacture and distribution of various biotechnological products. FBIOX’s 3-year and 5-year annualized returns are 16.1% and 23.7%, respectively. Annual expense ratio of 0.74% is lower than the category average of 1.35%. FBIOX has a Zacks Mutual Fund Rank #2. Link to the original post on Zacks.com